Supporting oncology professionals through education
The content on this site is intended for healthcare professionals only
The content on this site is intended for healthcare professionals only
Effects of short (6 months) and long (18 months) term treatment with gh-receptor antagonist pegvisomant (peg) on rhythm disturbances in acromegaly
Renata Auriemma, Federico II University of Naples, Italy
Long term treatment with pegvisomant in acromegalic patients results in significant improvement in cardiac rhythm, with low incidence of adverse events
Cardiovascular risk factors in treatment-resistant, active and long-term acromegaly: comparison to matched data from the general population and the effect of disease control
Christian Berg, University Hospital of Essen, Germany
In addition to being associated with an increase risk of cardiomyopathy, patients with acromegaly also experience a significant increase in the risk of CHD.
Pegvisomant significantly reduces the risk of CV risk in acromegalic patients, particularly in patients with normalised IGF-1 levels
We are an independent charity and are not backed by a large company or society. We raise every penny ourselves to improve the standards of cancer care through education. You can help us continue our work to address inequalities in cancer care by making a donation.
Any donation, however small, contributes directly towards the costs of creating and sharing free oncology education.
Together we can get better outcomes for patients by tackling global inequalities in access to the results of cancer research.
Thank you for your support.